SparingVision: Clinical Trials

5 trials sponsored by SparingVision, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 recruiting, 1 unknown. 2 Not applicable, 2 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Not applicable2Active not recruiting 1, Recruiting 1
Phase 12Active not recruiting 1, Recruiting 1
Phase 22Active not recruiting 1, Recruiting 1

Follow SparingVision: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Natural History Study of Advanced RCD
Eye examinations, Questionnaire - Rod Cone Dystrophy
Not applicableRecruitingSparingVision1002026-09-112026-10-08
Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy
SPVN20 (high dose), SPVN20 (medium dose), SPVN20 (low dose) - Retinitis Pigmentosa (RP), Rod Cone Dystrophy
Phase 1 / Phase 2RecruitingSparingVision272025-10-082026-09-08
Promising ROd-cone DYstrophy Gene therapY
SPVN06 - Retinitis Pigmentosa
Phase 1 / Phase 2Active not recruitingSparingVision332023-04-122026-05-15
Prospective Natural History Study of Retinitis Pigmentosa
Ophthalmic examinations, Mobility Test - Retinitis Pigmentosa
Not applicableActive not recruitingSparingVision822020-02-122025-05-22
Retrospective Natural History Study of Retinitis Pigmentosa
Retinitis Pigmentosa (RP)
UnknownSparingVision1132018-10-012021-08-04

Conditions studied

Cone-Rod Dystrophies (5)  ·  Retinitis Pigmentosa (5)  ·  Eye Diseases (4)  ·  Retinal Diseases (4)  ·  Blindness (2)  ·  Retinal Degeneration (2)  ·  Retinal Dystrophies (2)  ·  Vision Disorders (2)

Interventions

Surveys and Questionnaires (1)

Countries

France (5)  ·  Belgium (2)  ·  Ireland (2)  ·  United States (2)

Top investigators

Isabelle Audo, MD, PhD (1)

Results publications

PMID 40759732, PMID 41769936

NIH funding

2025 (1)